Cybin appoints dr. atul mahableshwarkar m.d., as senior vice president, clinical development

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that dr. atul r. mahableshwarkar m.d., dlfapa, has joined the company as senior vice president, clinical development. dr. mahableshwarkar will lead the development of the cyb003 program, cybin's prop.
CYBN Ratings Summary
CYBN Quant Ranking